Potential of targeted drug delivery system for the treatment of bone metastasis

References

• Adwan H, Berger M, Baeuerle T, Armbruster F, inventor; Deutsches Krebsforsch, Immundiagnostik Ag, Hassan Adwan, Martin Berger, Tobias Baeuerle, Franz Armbruster, applicant. Antisense oligonucleotides for prevention of metastasis formation of cancer cells. PCT/EP2004/009738. 24 March 2005
   Google Scholar
• Amgen.com. (2014). Amgen – medical professionals – products. [online] Available from: http://www.amgen.com/medpro/products_prolia.html [last accessed 19 Mar 2014]
   Google Scholar
• AstraZeneca. AZD0530 (saracatinib). Available from: http://www.ncats.nih.gov/files/AZD0530.pdf [last accessed 19 Mar 2014]
   Google Scholar
• Boender P, Bratland A, Hansen Ree A, Ruijtenbeek R, inventors; Rikshospitalet- Radiumhospitalet HF, PamGene BV, applicants. Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer. EP 2157971 A2. 3 Mar 2010
   Google Scholar
• Booth R, inventor; Virobay, Inc., applicant. Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain. PCT/US2005/001139. PCT/US2012/036184. 8 Nov 2012
   Google Scholar
• Cancer.gov. (2014a). NCI Drug Dictionary – National Cancer Institute. [online] Available from: http://www.cancer.gov/drugdictionary?cdrid=615854 [last accessed 19 Mar 2014]
   Google Scholar
• Cancer.gov. (2014b). NCI Dictionary of Cancer Terms – National Cancer Institute [online]. Available from: http://www.cancer.gov/dictionary?CdrID=45029 [last accessed 19 Mar 2014]
   Google Scholar
• Cancer research UK. (2013). Denosumab (Prolia, Xgeva). [online] http://www.cancerresearchuk.org/cancer-help/about-cancer/treatment/cancerdrugs/denosumab
   Google Scholar
• Chaudhari RK, Kumar A, Khelwal VK, et al. (2011). Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel. J Control Release 158:470–8
   PubMed Web of Science ®Google Scholar
• Chen B, Sun K. (2005). Poly (3-caprolactone)/hydroxyapatite composites: effects of particle size, molecular weight distribution and irradiation on interfacial interaction and properties. Polymer Testing 24:64–70
   Google Scholar
• Chiappori AA, Haura E, Rodriguez FA, et al. (2008). Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res 14:1464–9
   PubMed Web of Science ®Google Scholar
• Chung L, Josson S, Gururajan M, Jain A, inventors; Cedars-Sinai Medical Center, applicant. Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer. PCT/US2012/067403. 6 Jun 2013
   Google Scholar
• Clementi C, Miller K, Mero A, et al. (2011). Dendritic poly (ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms. Mol Pharm 8:1063–72
   PubMed Web of Science ®Google Scholar
• Ctmm.nl. (2014). [online]. Available at: http://www.ctmm.nl/en/downloads/full-article-downloads-pdf/full-article-on-project-hifu-chem [last accessed 20 Mar 2014]
   Google Scholar
• Daubine F, Cortial D, Ladam G, et al. (2009). Nanostructured polyelectrolyte multilayer drug delivery systems for bone metastasis prevention. Biomaterials 30:6367–73
   PubMed Web of Science ®Google Scholar
• Fatatis A, Huber J, Loizos N, et al., inventors; Drexel University College Of M, Alessandro Fatatis, Jim Huber, Imclone Systems Inc, Nick Loizos, Dale L Ludwig, Stephen R Plymate, Univ Washington., applicant. Receptor antagonists for treatment of metastatic bone cancer. PCT/US2006/023856. 12 Feb 2009
   Google Scholar
• Fda.gov. (2014). FDA approves additional medical indication for Sprycel. [online] Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm231409.htm [last accessed 19 Mar 2014]
   Google Scholar
• Galmarini CM. (2009). Sagopilone, a microtubule stabilizer for the potential treatment of cancer. Cur Opin Investig Drugs 10:1359–71
   PubMed Web of Science ®Google Scholar
• Gu W, Wu C, Chen J, Xiao Y. (2013). Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration. Int J Nanomed 8:2305–17
   PubMed Web of Science ®Google Scholar
• Guise T. (2010). Examining the metastatic niche: targeting the microenvironment. Semin Oncol 37:2–14
   PubMed Web of Science ®Google Scholar
• Herper M. (2012). Has Merck found the heir to Fosamax? [online]. Available from: http://www.forbes.com/sites/matthewherper/2012/07/11/has-merck-found-the-heir-to-fosamax/ [last accessed 19 Mar 2014]
   Google Scholar
• Kopeček J, Kopeckov' AP. (2010). HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev 62:122–49
   PubMed Web of Science ®Google Scholar
• Le Gall C, Bonnelye E, Clezardin P. (2008). Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care 2:218–22
   PubMedGoogle Scholar
• Lee J, Nan A. (2012). Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv 2012:1–17
   Google Scholar
• Low SA, Kopevcek J. (2012). Targeting polymer therapeutics to bone. Adv Drug Deliv Rev 64:1189–204
   PubMed Web of Science ®Google Scholar
• Nam H, Im S, Oh D, et al. (2013). Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer. Mol Cancer Ther 12:16–26
   PubMed Web of Science ®Google Scholar
• Nasim S, Vartak A, Pierce Jr WM, et al. (2010a). Improved and scalable synthetic route to the synthon 17-(2-carboxyethyl)-1,3,5 (10)-estratriene: an important intermediate in the synthesis of bone-targeting estrogens. Synth Commun 40:772–81
   Google Scholar
• Nasim S, Vartak AP, Pierce Jr WM, et al. (2010b). 3-O-Phosphate ester conjugates of 17-β-O-{1-[2-carboxy-(2-hydroxy-4-methoxy-3-carboxamido) anilido]ethyl}1,3,5(10)-estratriene as novel bone-targeting agents. Bioorg Med Chem Lett 20:7450–53
   Google Scholar
• National Cancer Institute. (2014). NCI Drug Dictionary Sacratinib. Available from: http://www.cancer.gov/drugdictionary?cdrid=453588 [last accessed 19 Mar 2014]
   Google Scholar
• Neale J, Richter NB, Merten KE, et al. (2009). Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent. Bioorg Med Chem Lett 19:680–3
   Google Scholar
• Novartis AG, De giovanni, Carla lollini, Pier-luigi nanni, Patrizia, applicants. PI3K inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone. PCT/EP/2012/067019. 7 March 2013
   Google Scholar
• Oakervee HE, Popat R, Curry N, et al. (2005). PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 129:755–62
   PubMed Web of Science ®Google Scholar
• Persson BE, inventor; Ferring International Center S.A., applicant. Treatment of metastatic stage prostate cancer with degarelix. EP 2650012 A1. 16 Oct 2013
   Google Scholar
• Qiao C, Zhang K, Jin H, et al. (2013). Using poly (lactic-co-glycolic acid) microspheres to encapsulate plasmid of bone morphogenetic protein 2/polyethylenimine nanoparticles to promote bone formation in vitro and in vivo. Int J Nanomed 8:2985–95
   PubMed Web of Science ®Google Scholar
• Rabbani S, Shukeir N, Panchal C, Newman C, Inventors; Rabbani Shafaat Ahmed, Nicholas Shukeir, Panchal Chandra J, Christopher Newman, original assignee. PSP-94: use for treatment of hypercalcemia and bone metastasis. US 10/857,358. 3 Feb 2005
   Google Scholar
• Razak S, Sharif N, Rahman W. (2012). Biodegradable polymers and their bone applications: a review. Int J Basic Appl Sci 12:31–49
   Google Scholar
• Richert MM, Vaidya KS, Mills CN, et al. (2009). Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep 21:761–7
   PubMed Web of Science ®Google Scholar
• Rogers MJ, Watts DJ, Russell RGG. (1997). Overview of bisphosphonates. Cancer 80:1652–60
   PubMed Web of Science ®Google Scholar
• Roodman G. (2004). Mechanisms of bone metastasis. N Eng J Med 350:1655–64
   PubMed Web of Science ®Google Scholar
• Rose A, Siegel P. (2010). Emerging therapeutic targets in breast cancer bone metastasis. Future Oncology 6:55–74
   Google Scholar
• Salerno M, Cenni E, Fotia C, et al. (2010). Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. Curr Cancer Drug Targets 10:649–59
   PubMed Web of Science ®Google Scholar
• Sands A, inventor; Lexicon Pharmaceuticals Inc., applicant. Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease. PCT/US2011/024141. 18 Aug 2011
   Google Scholar
• Shiels S, Solomon K, Pilia M, et al. (2012). BMP-2 tethered hydroxyapatite for bone tissue regeneration: coating chemistry and osteoblast attachment. J Biomed Mater Res A 100:3117–23
   PubMed Web of Science ®Google Scholar
• Suva LJ, Griffin RJ, Makhoul I. (2009). Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer 16:703–13
   PubMed Web of Science ®Google Scholar
• Thamake SI, Raut SL, Gryczynski Z, et al. (2012). Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials 33:7164–73
   PubMed Web of Science ®Google Scholar
• Thein-Han WW, Misra RDK. (2009). Biomimetic chitosan–nanohydroxyapatite composite scaffolds for bone tissue engineering. Acta Biomaterialia 5:1182–97
   Google Scholar
• Wong M, Pavlakis N. (2011). Optimal management of bone metastases in breast cancer patients. Breast Cancer 3:35–60
   PubMedGoogle Scholar
• Zhang S, Wang G, Lin X, et al. (2008). Polyethylenimine-coated albumin nanoparticles for BMP-2 delivery. Biotechnol Prog 24:945–56
   PubMed Web of Science ®Google Scholar
• Zhang S, Wright N, Uludağ H. (2007). The interaction of cationic polymers and their bisphosphonate derivatives with hydroxyapatite. Macromol Biosci 7:656–70
   PubMed Web of Science ®Google Scholar